Evidence map›Paper›PMID 40729048›Full record

SynthesisAsian Pacific journal of cancer prevention : APJCP2025

Efficacy and Safety of Tebentafusp in Uveal Melanoma: A Systematic Review and Single-Arm Meta-Analysis.

Majid M AlBarakat, Ahmed Wadaa-Allah, Rana B Altawalbeh, Khaled M Hamam, Dana Y Tarawneh, Abdullah Al Momani, Sakhr Alshwayyat, Arvind Kunadi

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Majid M AlBarakatFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Ahmed Wadaa-AllahBiochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.ORCID 0000-0002-9678-7359
Rana B AltawalbehFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Khaled M HamamResearch Scholar, Pharmaceutical Sciences Department, College of Health and Human Sciences, North Dakota State University, Fargo, North Dakota, USA.
Dana Y TarawnehSchool of Medicine, the University of Jordan, Amman, Jordan.
Abdullah Al MomaniFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Sakhr AlshwayyatResearch Associate, King Hussein Cancer Center, Amman, Jordan.
Arvind KunadiMcLaren Health Care, Flint, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUveal melanoma, a rare and aggressive intraocular malignancy, poses significant challenges due to its high metastatic potential. Tebentafusp, an innovative immunotherapy targeting melanoma-associated antigens, has shown promise in early clinical trials for metastatic uveal melanoma.

methodsThis systematic review adhered to PRISMA guidelines, analyzing four studies encompassing 475 patients until January 18, 2024. Meta-analysis techniques, utilizing RevMan software version 5.4, were employed to calculate hazard ratios (HR) or risk ratios (RR) with their respective 95% confidence intervals for each outcome.

resultsThe 1-year overall survival rate, pooled from the included studies, was 68% with moderate heterogeneity (I2=56%, p=0.1). Cytokine release syndrome was observed in 83% of patients across three studies, with high heterogeneity (I2=79%, p<0.01).

conclusionOur findings underscore modest responses and manageable adverse effects such as cytokine release syndrome and fatigue, highlighting the necessity for careful monitoring and proactive management in the clinical application of Tebentafusp for metastatic uveal melanoma.

Indexed as

ImmunotherapyMelanomaUveal NeoplasmsHumansPrognosisSurvival RateUveal MelanomaMeta-analysisSystematic reviewTebentafuspuveal melanoma

Identifiers

PMID40729048
PMCPMC12507063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.